In accordance with this hypothesis, perfusion measurements with MRI and pulsed arterial spin labeling have proven that the A2AR antagonist tozadenant inhibits (i.e., suppresses the overactivity of) the indirect pathway in the brain of Parkinson’s patients [152]. The gene discussed is ADORA2A; the disease is Parkinson disease.